Alpha-blockade: Monotherapy for hypertension and benign prostatic hyperplasia

Extracts from "Clinical Evidence": Benign prostatic hyperplasia

“…11 19 Prazosin, alfuzosin, terazosin, and doxazosin lower blood pressure and may be used to treat both hypertension and BPH 20. The three subsequent RCTs comparing α blockers are limited by their small sample sizes, short duration (4,13414 and 1615 weeks), low drug doses, and unclear methods of randomisation and blinding.…”

Benign Prostatic Hyperplasia

“…11 19 Prazosin, alfuzosin, terazosin, and doxazosin lower blood pressure and may be used to treat both hypertension and BPH. 20 The three subsequent RCTs comparing blockers are limited by their small sample sizes, short duration (4, 13 4 14 and 16 15 weeks), low drug doses, and unclear methods of randomisation and blinding.…”

Recent Advances in α1-Adrenoreceptor Antagonists as Pharmacological Tools and Therapeutic Agents

“…The effort to design agents selective for each of the three α 1 -AR subtypes has been an active area of research because of the wide number of possible therapeutic applications. Initially introduced for the management of hypertension [3,4], α 1 -AR antagonists have become increasingly common in the treatment of BPH, where they reduce the 'dynamic' component of bladder outlet obstruction and appear to have additional actions to reduce the irritative symptoms of the disease [5][6][7].…”